A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice - Wikidata - awgldk - TriplyDB

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice

http://www.wikidata.org/entity/Q34559952

about

HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders Novel concepts in HDL pharmacology.Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro Tomatoes, lysophosphatidic acid, and the small intestine: new pieces in the puzzle of apolipoprotein mimetic peptides?Swapping the N- and C-terminal domains of human apolipoprotein E3 and AI reveals insights into their structure/activity relationship A pyrene based fluorescence approach to study conformation of apolipoprotein E3 in macrophage-generated nascent high density lipoprotein.5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.Structure and lipid interactions of an anti-inflammatory and anti-atherogenic 10-residue class G(*) apolipoprotein J peptide using solution NMR.Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.Evolving targets for lipid-modifying therapy A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution Acrolein modification impairs key functional features of rat apolipoprotein E: identification of modified sites by mass spectrometry.Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter.Novel HDL-directed pharmacotherapeutic strategies.Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.Quercetin enhances ABCA1 expression and cholesterol efflux through a p38-dependent pathway in macrophages Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins.ABCA1 agonist peptides for the treatment of disease.Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter.Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO.Amphipathic polyproline peptides stimulate cholesterol efflux by the ABCA1 transporter.HDL, Atherosclerosis, and Emerging Therapies Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs.Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.Recombinant high-density lipoprotein formulations.HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.Progress in HDL-based therapies for atherosclerosis.Apolipoprotein E mimetics and cholesterol-lowering properties.New lipid-lowering drugs: an update.HDL quality and functionality: what can proteins and genes predict?An overview of the new frontiers in the treatment of atherogenic dyslipidemias.

P2860

Q27691344-8F001E13-1F24-403B-8F07-1F98882E8864 Q27692691-A3657EF5-EA9A-465D-8EDF-A51E9AF20CD9 Q28546760-611A155C-3AAD-47BC-8C88-20D1FABF93F9 Q33356762-5DFE3CED-6B2C-4651-ACB2-CB12121E4AE9 Q33828806-30AA05EB-6073-42A6-A6FF-88823184EB3F Q34033587-1E650793-6EDA-494B-B395-34CE62B69E68 Q34035255-9A9596C2-732E-46BC-B942-27560FCA4CF7 Q34144449-1FC5B37F-590A-4471-9966-3E53391208F2 Q34238630-445C10AA-EE02-4598-9E4D-0C56C4C3FB13 Q34238652-A0531571-E239-45AE-9E85-4381D63570A3 Q34384359-67F702CE-9E5A-4840-A476-5C5330C01987 Q34594140-C15D776B-3D07-400B-AF7A-BED74A0D1BAF Q34781496-E92361CB-7C7E-47F2-B9E3-66BAFE794036 Q34851167-6B448A1C-4F14-4EC8-8E0A-8846F3C10F20 Q34880292-8AC3BDD4-E2BC-4BF5-AF2A-781D7B56F23B Q34946523-10D9F008-495D-450C-9A39-ACC52ABCA08F Q34955938-F2D4BFA4-2D4A-41B6-AE04-B9E598F9BD89 Q35001010-62CECB31-DB83-4CC1-872A-C38A115A8659 Q35064519-F5DC288A-7166-4E4F-9DF2-7AA77DD674EF Q35660283-C038F293-D2D1-481F-A8DF-5F7C48E2F522 Q35860020-2358A6C5-6634-47C1-B888-8DC9E17F4256 Q36007212-5E91547F-BC78-4B21-9425-A84369F1BCDF Q36145207-208D3B0E-E576-4C9B-93A5-D7DEAF34803D Q36185793-1D130F24-B998-41DC-ADB0-970B465F8A86 Q36436785-25F41452-FCFB-44CA-B1B1-C22EDDFDF076 Q36497600-D66011E7-F0D8-400C-A22B-EB3909A4F637 Q36553833-883F4927-235A-43B8-A449-A0186CBD4DF2 Q36761029-17D397A5-DA0C-4052-8714-BB56D703CD4A Q36918309-9E3B2255-F252-4102-B603-15E51DABEF29 Q37033119-AE045E81-9757-4FC7-9325-B4786F3CFDE7 Q37340299-BF1A4CCE-75A0-410C-8520-D2B6252D654B Q37671683-9057A72F-8E39-4670-9811-4BC2497ADE22 Q37702199-B95C12DC-E373-4596-935F-95E34E2C78EA Q37807911-FEA2AF40-3E5F-4ADB-A5C5-25055617E425 Q37838234-3CA3A3D2-25F6-4A95-89DB-EB88DA10844D Q37899798-58D10303-1588-4357-B57B-D7D7C508943E Q37965590-78FFEDC2-EB98-475A-9F3F-CA09872B3C64 Q37984782-E463931B-4E34-4B73-8DC4-86D7E0E35E42 Q38197735-C76D8A6F-EA2E-44C2-ABD6-1DCE2D309D33 Q38204183-BFA03D22-AEDA-4B57-A5A9-70091BD14BF3

P2860

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice

http://www.wikidata.org/entity/Q34559952

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@ast

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@en

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@nl

type

label

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@ast

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@en

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@nl

prefLabel

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@ast

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@en

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@nl

P1433

Q34559952-79922A8B-5380-4F7F-94AC-75B4C7317C9F

P1476

Q34559952-C18CF63E-DC41-4AD3-BF9D-5F35C3CD265F

P2093

Q34559952-214AE3EF-E845-4639-A82D-7528264AEA8C

Q34559952-2994C0FF-D681-4381-8274-F9F5F6C4D0B6

Q34559952-3387861D-A2FB-4467-83BB-6DCF2FEEC734

Q34559952-401F719B-8A47-400E-90CF-36FB5991A1E1

Q34559952-50EA28C1-A77C-4DA1-B491-72A9B011A7CB

Q34559952-863BA740-DD13-42AF-929D-629166EC71E1

Q34559952-B970B183-BDAF-45EF-9135-6F7958E8AA05

Q34559952-E87B95AD-FECE-4624-A617-58D0FB22570C

P2860

Q34559952-08A8161F-ED4B-4975-9BE7-B7F92AD2573C

Q34559952-1216EA0E-7E32-401E-ABEB-8B9433B8AE1B

Q34559952-1BFA19E5-A1C8-4DDC-9333-212E4E88B2A8

Q34559952-288023BA-FC5A-463C-875D-D63A5F4B870C

Q34559952-2DA323D9-755E-47E9-B23C-DEBCA0BBC0A5

Q34559952-34E8733A-AD92-41B7-B73B-D1FDF4A247F1

Q34559952-37A2C30C-29B1-4B79-B13C-B4AE6EBB1997

Q34559952-3B77C7E9-0EF3-4164-889F-7015A6BBF67B

Q34559952-46155B07-AE44-4DF5-A12B-12527BA9D2B4

Q34559952-5CAEE151-AD0B-48F3-AB85-E2318894F9C0

P304

Q34559952-73897281-A6A4-4454-A06A-8489BCAE3AED

P31

Q34559952-A8F0A65C-0ADB-49F8-AA6C-88BEAC6E1E0F

P356

Q34559952-85B9B8B8-68A7-4E34-94B1-C43E5EA96AB1

P433

Q34559952-9C73D586-6069-4F09-AB4A-E792DDBD3822

P478

Q34559952-AA5F1BE3-AB10-4A22-9201-5477F300BDE6

P577

Q34559952-B675C62C-3ED9-439E-960E-2A4F811556DD

P698

Q34559952-88718BFB-7DA3-4506-B928-01857D57D418

P921

Q34559952-FAB932BF-B30A-4CDE-A041-8A6D3DA75A12

P932

Q34559952-E7D8E6CB-5582-41B0-894D-D9F2859C6801

P356

P1433

Journal of Lipid Research

P1476

A new HDL mimetic peptide that ...... educes atherosclerosis in mice

@en

P2093

Arti Patel

http://www.w3.org/2001/XMLSchema#string

Haiyan Zhang

http://www.w3.org/2001/XMLSchema#string

Jan Johansson

http://www.w3.org/2001/XMLSchema#string

John K Bielicki

http://www.w3.org/2001/XMLSchema#string

Salman Azhar

http://www.w3.org/2001/XMLSchema#string

Vasanthy Narayanaswami

http://www.w3.org/2001/XMLSchema#string

Ying Zheng

http://www.w3.org/2001/XMLSchema#string

Yuan Cortez

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein specificity for lipid efflux by the human ABCAI transporter

The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo

New insights into the regulation of HDL metabolism and reverse cholesterol transport.

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans.

The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function.

Apolipoprotein A-I mimetic peptides.

Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis.

P304

1496-1503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.M003665

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20075422

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

3035513

http://www.w3.org/2001/XMLSchema#string